Cinciripini 2013.

Methods	BUPROPION Randomized controlled trial Setting: clinic, USA Recruitment: community volunteers
Participants	294 smokers of ≥ 5 cpd 61% M, av age 44, av cpd 20, mean FTND 4.5
Interventions	1. 12 weeks bupropion started 12‐19 days before TQD (150mg/d days 1‐3, 300mg/d thereafter) 2. 12 weeks varenicline on same schedule (0.5mg/day days 1‐3, 1.0mg/day days 4‐7, 2.0mg/day thereafter) 3. Placebo on same schedule All arms: 10 individual counselling sessions (6 in person, 4 via phone, 240 mins total)
Outcomes	Continuous abstinence after 2 week grace period at 6m (Other prolonged abstinence outcomes also reported) Validation: CO < 10 ppm or salivary cotinine < 15 ng/mL
Notes	New for 2013 In less than 1% of the total cases, participants who did not attend a follow‐up were coded as abstinent because they were abstinent at the following data point. All other losses to follow‐up counted as smokers. Author provided further detail on AE measurements via e‐mail. Funding: National Institute on Drug Abuse, National Cancer Institute
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	“Adaptive randomization,” no further detail provided
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	“Blinded” but no further information provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	73% followed up at 6m, similar rates across arms, all lost to follow‐up known to be smokers